

# Alexander A Vinks

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9203892/alexander-a-vinks-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

154  
papers

3,932  
citations

31  
h-index

58  
g-index

175  
ext. papers

4,991  
ext. citations

4.4  
avg, IF

5.45  
L-index

#	Paper	IF	Citations
154	Methodologic Progress Note: Opportunistic Sampling for Pharmacology Studies in Hospitalized Children. <i>Journal of Hospital Medicine</i> , <b>2021</b> , 16, 35-37	2.7	5
153	Physiologically-Based Pharmacokinetic Modeling to Investigate the Effect of Maturation on Buprenorphine Pharmacokinetics in Newborns with Neonatal Opioid Withdrawal Syndrome. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> ,	6.1	2
152	Pharmacokinetics of L-Glutamine (Endari) in Pediatric and Adult Sickle Cell Disease Patients: A Phase 4, Open-Label, Single-Center Study. <i>Blood</i> , <b>2021</b> , 138, 980-980	2.2	
151	A review of pregnancy-induced changes in opioid pharmacokinetics, placental transfer, and fetal exposure: Towards fetomaternal physiologically-based pharmacokinetic modeling to improve the treatment of neonatal opioid withdrawal syndrome. <i>Pharmacology &amp; Therapeutics</i> , <b>2021</b> , 108045	13.9	2
150	Population Pharmacokinetic Modeling of Total and Free Ceftriaxone in Critically Ill Children and Young Adults and Monte Carlo Simulations Support Twice Daily Dosing for Target Attainment. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2021</b> , AAC0142721	5.9	0
149	Therapeutic Drug Monitoring in the Era of Precision Medicine: Achievements, Gaps, and Perspectives-An Interview in Honor of Professor Charles Pippenger. <i>Therapeutic Drug Monitoring</i> , <b>2021</b> , 43, 719-727	3.2	1
148	Low-dose Dasatinib Ameliorates Hypertrophic Cardiomyopathy in Noonan Syndrome with Multiple Lentigenes. <i>Cardiovascular Drugs and Therapy</i> , <b>2021</b> , 1	3.9	2
147	NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 797-806	2.2	16
146	Model-Informed Pediatric Drug Development: Application of Pharmacometrics to Define the Right Dose for Children. <i>Journal of Clinical Pharmacology</i> , <b>2021</b> , 61 Suppl 1, S52-S59	2.9	0
145	Toward pharmacogenetic SLCO1B1-guided dosing of methotrexate in arthritis using a murine Slco1b2 knockout model. <i>Clinical and Translational Science</i> , <b>2021</b> , 14, 2267-2277	4.9	1
144	Status Toward the Implementation of Precision Dosing in Children. <i>Journal of Clinical Pharmacology</i> , <b>2021</b> , 61 Suppl 1, S36-S51	2.9	2
143	Test-dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non-malignant disorders. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> ,	3.8	1
142	Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia. <i>British Journal of Haematology</i> , <b>2021</b> , 194, 617-625	4.5	2
141	Sirolimus Treatment in Sturge-Weber Syndrome. <i>Pediatric Neurology</i> , <b>2021</b> , 115, 29-40	2.9	3
140	Pharmacotherapy of neonatal opioid withdrawal syndrome: a review of pharmacokinetics and pharmacodynamics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2021</b> , 17, 87-103	5.5	5
139	Hydroxyurea Pharmacokinetics in Pediatric Patients After Total Pancreatectomy With Islet Autotransplantation. <i>Journal of Clinical Pharmacology</i> , <b>2021</b> , 61, 547-554	2.9	1
138	A Pilot Randomized, Controlled, Double-Blind Trial of Bumetanide to Treat Neonatal Seizures. <i>Annals of Neurology</i> , <b>2021</b> , 89, 327-340	9.4	16

137	Roger W. Jelliffe, MD, FCP, FAAPS: A World Leader in Population Pharmacokinetic and Pharmacodynamic Modeling and Model-Based Target Controlled Individualized Dosing. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 109, 22-24	6.1	
136	Demonstrating Feasibility of an Opportunistic Sampling Approach for Pharmacokinetic Studies of $\beta$ -Lactam Antibiotics in Critically Ill Children. <i>Journal of Clinical Pharmacology</i> , <b>2021</b> , 61, 565-573	2.9	3
135	A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma. <i>Pediatric Blood and Cancer</i> , <b>2021</b> , 68, e28787	3	6
134	Physiologic Indirect Response Modeling to Describe Buprenorphine Pharmacodynamics in Newborns Treated for Neonatal Opioid Withdrawal Syndrome. <i>Clinical Pharmacokinetics</i> , <b>2021</b> , 60, 249-259	6.3	4
133	Pharmacokinetic modelling to predict risk of ototoxicity with intravenous tobramycin treatment in cystic fibrosis. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2021</b> , 76, 2923-2931	5.1	1
132	Hydroxyurea improves cerebral oxygen saturation in children with sickle cell anemia. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 538-544	7.1	0
131	Paperspray Ionization Mass Spectrometry as a Tool for Predicting Real-Time Optimized Dosing of the Chemotherapeutic Drug Melphalan. <i>Journal of Applied Laboratory Medicine</i> , <b>2021</b> , 6, 625-636	2	2
130	Opioid Treatment for Neonatal Opioid Withdrawal Syndrome: Current Challenges and Future Approaches. <i>Journal of Clinical Pharmacology</i> , <b>2021</b> , 61, 857-870	2.9	6
129	Model-informed precision dosing for alemtuzumab in paediatric and young adult patients undergoing allogeneic haematopoietic cell transplantation. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> ,	3.8	4
128	A prospective pilot study of a novel alemtuzumab target concentration intervention strategy. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 3029-3031	4.4	2
127	Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's Disease. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 109, 1639-1647	6.1	12
126	Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> ,	6.1	1
125	Clinical implementation of pharmacogenetics and model-informed precision dosing to improve patient care. <i>British Journal of Clinical Pharmacology</i> , <b>2020</b> ,	3.8	6
124	MTXPK.org: A Clinical Decision Support Tool Evaluating High-Dose Methotrexate Pharmacokinetics to Inform Post-Infusion Care and Use of Glucarpidase. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 108, 635-643	6.1	13
123	Influence of MRP3 Genetics and Hepatic Expression Ontogeny for Morphine Disposition in Neonatal and Pediatric Patients. <i>Journal of Clinical Pharmacology</i> , <b>2020</b> , 60, 992-998	2.9	5
122	A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 1527-1535	1	20
121	Hydroxyurea Exposure in Lactation: a Pharmacokinetics Study (HELPS). <i>Journal of Pediatrics</i> , <b>2020</b> , 222, 236-239	3.6	3
120	Model-Informed Development of Sotalol Loading and Dose Escalation Employing an Intravenous Infusion. <i>Cardiology Research</i> , <b>2020</b> , 11, 294-304	1.8	3

119	PK/PD Study of Mycophenolate Mofetil in Children With Systemic Lupus Erythematosus to Inform Model-Based Precision Dosing. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 605060	5.6	3
118	Electrochemical Determination of Hydroxyurea in a Complex Biological Matrix Using MoS-Modified Electrodes and Chemometrics. <i>Biomedicines</i> , <b>2020</b> , 9,	4.8	1
117	Development and Implementation of Electronic Health Record-Integrated Model-Informed Clinical Decision Support Tools for the Precision Dosing of Drugs. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 107, 129-135	6.1	18
116	Next Challenge From the Variance in Individual Physiologically-Based Pharmacokinetic Model-Predicted to Observed Morphine Concentration in Critically Ill Neonates. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 107, 319-320	6.1	2
115	Population pharmacokinetic modelling of busulfan and the influence of body composition in paediatric Fanconi anaemia patients. <i>British Journal of Clinical Pharmacology</i> , <b>2020</b> , 86, 933-943	3.8	3
114	Utilizing Pediatric Physiologically Based Pharmacokinetic Models to Examine Factors That Contribute to Methadone Pharmacokinetic Variability in Neonatal Abstinence Syndrome Patients. <i>Journal of Clinical Pharmacology</i> , <b>2020</b> , 60, 453-465	2.9	5
113	Molecular Adsorbent Recirculating System Therapy with Continuous Renal Replacement Therapy Enhanced Clearance of Piperacillin in a Pediatric Patient and Led to Failure to Attain Pharmacodynamic Targets. <i>Pharmacotherapy</i> , <b>2020</b> , 40, 1061-1068	5.8	3
112	Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia. <i>Trials</i> , <b>2020</b> , 21, 983	2.8	6
111	Hydromorphone population pharmacokinetics in pediatric surgical patients. <i>Paediatric Anaesthesia</i> , <b>2020</b> , 30, 1091-1101	1.8	2
110	Model-Informed Bayesian Estimation Improves the Prediction of Morphine Exposure in Neonates and Infants. <i>Therapeutic Drug Monitoring</i> , <b>2020</b> , 42, 778-786	3.2	4
109	Electronic Health Record-Embedded Decision Support Platform for Morphine Precision Dosing in Neonates. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 107, 186-194	6.1	15
108	Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , <b>2020</b> , 26, 429-439	4.5	20
107	Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib. <i>Pediatric Blood and Cancer</i> , <b>2019</b> , 66, e27618	3	12
106	Significant effect of infection and food intake on sirolimus pharmacokinetics and exposure in pediatric patients with acute lymphoblastic leukemia. <i>European Journal of Pharmaceutical Sciences</i> , <b>2019</b> , 128, 209-214	5.1	6
105	Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 871-879	7.1	35
104	Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus. <i>American Journal of Transplantation</i> , <b>2019</b> , 19, 2944-2948	8.7	40
103	Evaluation of Clinical and Safety Outcomes Following Uncontrolled Tacrolimus Conversion in Adult Transplant Recipients. <i>Pharmacotherapy</i> , <b>2019</b> , 39, 564-575	5.8	2
102	A Theoretical Physiologically-Based Pharmacokinetic Approach to Ascertain Covariates Explaining the Large Interpatient Variability in Tacrolimus Disposition. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2019</b> , 8, 273-284	4.5	15

101	Pediatric Phase II Study of Maraviroc for Acute Graft Versus Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, S251-S252	4.7	2
100	Recommendations for the design of therapeutic trials for neonatal seizures. <i>Pediatric Research</i> , <b>2019</b> , 85, 943-954	3.2	28
99	Implementation of Pharmacogenetics at Cincinnati Children's Hospital Medical Center: Lessons Learned Over 14 Years of Personalizing Medicine. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 105, 49-52	6.1	31
98	Busulfan Pharmacokinetics and Precision Dosing: Are Patients with Fanconi Anemia Different?. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 2416-2421	4.7	4
97	V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia. <i>Blood</i> , <b>2019</b> , 134, 3830-3830	2.2	1
96	Hydroxyurea Pharmacokinetic Profiles in Children Treated for Extreme Thrombocytosis after Total Pancreatectomy with Islet Cell Autotransplant Demonstrate Poor Absorption. <i>Blood</i> , <b>2019</b> , 134, 4893-4893	2.2	1
95	1543. Ceftaroline Model-based Dose Individualization in an Infant with Kidney Disease and Mediastinitis. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S563-S563	1	78
94	Route of Oseltamivir Administration Affects Metabolite Concentrations in Critically Ill Children. <i>Pediatric Infectious Disease Journal</i> , <b>2019</b> , 38, 1224-1227	3.4	3
93	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. <i>Therapeutic Drug Monitoring</i> , <b>2019</b> , 41, 261-307	3.2	163
92	Dose modifications and pharmacokinetics of adjuvant cisplatin monotherapy while on hemodialysis for patients with hepatoblastoma. <i>Pediatric Blood and Cancer</i> , <b>2019</b> , 66, e27425	3	3
91	Suggestions for Model-Informed Precision Dosing to Optimize Neonatal Drug Therapy. <i>Journal of Clinical Pharmacology</i> , <b>2019</b> , 59, 168-176	2.9	11
90	Developmental Pharmacokinetics and Age-Appropriate Dosing Design of Milrinone in Neonates and Infants with Acute Kidney Injury Following Cardiac Surgery. <i>Clinical Pharmacokinetics</i> , <b>2019</b> , 58, 793-803	6.2	9
89	Assessment of tacrolimus inpatient variability in stable adherent transplant recipients: Establishing baseline values. <i>American Journal of Transplantation</i> , <b>2019</b> , 19, 1410-1420	8.7	44
88	Influence of OCT1 Ontogeny and Genetic Variation on Morphine Disposition in Critically Ill Neonates: Lessons From PBPK Modeling and Clinical Study. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 105, 761-768	6.1	27
87	Micafungin antifungal prophylaxis in children undergoing HSCT: can we give higher doses, less frequently? A pharmacokinetic study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, 1651-1658	5.1	3
86	Model-based dosing with concentration feedback as an integral part of personalized hydroxycarbamide management. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 1410-1412	3.8	1
85	Using a Vancomycin PBPK Model in Special Populations to Elucidate Case-Based Clinical PK Observations. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2018</b> , 7, 237-250	4.5	10
84	Acute Kidney Injury Biomarkers Predict an Increase in Serum Milrinone Concentration Earlier Than Serum Creatinine-Defined Acute Kidney Injury in Infants After Cardiac Surgery. <i>Therapeutic Drug Monitoring</i> , <b>2018</b> , 40, 186-194	3.2	11

83	Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance. <i>Oncologist</i> , <b>2018</b> , 23, 52-61	5.7	63
82	Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation. <i>Clinical Pharmacokinetics</i> , <b>2018</b> , 57, 625-636	6.2	8
81	PBPK Model of Morphine Incorporating Developmental Changes in Hepatic OCT1 and UGT2B7 Proteins to Explain the Variability in Clearances in Neonates and Small Infants. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2018</b> , 7, 464-473	4.5	23
80	Clinical and Laboratory Benefits of Early Initiation of Hydroxyurea with Pharmacokinetic Guided Dosing for Young Children with Sickle Cell Anemia. <i>Blood</i> , <b>2018</b> , 132, 507-507	2.2	1
79	Hydroxyurea Exposure in Lactation Pharmacokinetics Study (HELPS). <i>Blood</i> , <b>2018</b> , 132, 3677-3677	2.2	3
78	Characterizing important determinants of Tacrolimus pharmacokinetic variability in renal transplant patients: PBPK modeling approach using genotyped patients information. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , <b>2018</b> , WCP2018, OR22-3	0	
77	Phase 1 safety and pharmacokinetic study on the use of pioglitazone in critically ill patients with sepsis: a randomized clinical trial. <i>Intensive Care Medicine</i> , <b>2018</b> , 44, 2006-2008	14.5	4
76	NFM-06. NF106: PHASE 2 TRIAL OF THE MEK INHIBITOR PD-0325901 IN ADOLESCENTS AND ADULTS WITH NF1-RELATED PLEXIFORM NEUROFIBROMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY. <i>Neuro-Oncology</i> , <b>2018</b> , 20, i143-i143	1	11
75	Pharmacokinetics of glycerol phenylbutyrate in pediatric patients 2 months to 2 years of age with urea cycle disorders. <i>Molecular Genetics and Metabolism</i> , <b>2018</b> , 125, 251-257	3.7	4
74	ABCC3 genetic variants are associated with postoperative morphine-induced respiratory depression and morphine pharmacokinetics in children. <i>Pharmacogenomics Journal</i> , <b>2017</b> , 17, 162-169	3.5	21
73	Measuring Medication Adherence in Pediatric Cancer: An Approach to Validation. <i>Journal of Pediatric Psychology</i> , <b>2017</b> , 42, 232-244	3.2	19
72	Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus. <i>Clinical Pharmacokinetics</i> , <b>2017</b> , 56, 107-125	6.2	5
71	Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group. <i>British Journal of Clinical Pharmacology</i> , <b>2017</b> , 83, 1097-1107	3.8	11
70	Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 635-641	4.7	17
69	Clinical Trial Simulations and Pharmacometric Analysis in Pediatrics: Application to Inhaled Loxapine in Children and Adolescents. <i>Clinical Pharmacokinetics</i> , <b>2017</b> , 56, 1207-1217	6.2	7
68	Developmental pharmacokinetics of sirolimus: Implications for precision dosing in neonates and infants with complicated vascular anomalies. <i>Pediatric Blood and Cancer</i> , <b>2017</b> , 64, e26470	3	46
67	CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients. <i>Pharmacogenomics</i> , <b>2017</b> , 18, 337-348	2.6	28
66	Time in therapeutic range as a marker for thrombotic and bleeding outcomes in Fontan patients. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2017</b> , 44, 38-47	5.1	15

65	OCT1 genetic variants are associated with postoperative morphine-related adverse effects in children. <i>Pharmacogenomics</i> , <b>2017</b> , 18, 621-629	2.6	28
64	Model-based precision dosing of sirolimus in pediatric patients with vascular anomalies. <i>European Journal of Pharmaceutical Sciences</i> , <b>2017</b> , 109S, S124-S131	5.1	25
63	Pharmacokinetics and Safety of Single-Dose Inhaled Loxapine in Children and Adolescents. <i>Journal of Clinical Pharmacology</i> , <b>2017</b> , 57, 1244-1257	2.9	6
62	Test Dose Pharmacokinetics to Predict Melphalan Dosing in Children Undergoing Hematopoietic Stem Cell Transplant (HSCT) with Organ Impairment?. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, S228	4.7	2
61	Pharmacokinetic and pharmacogenetic analysis of immunosuppressive agents after laparoscopic sleeve gastrectomy. <i>Clinical Transplantation</i> , <b>2017</b> , 31, e12975	3.8	20
60	Developmental Changes in Hepatic Organic Cation Transporter OCT1 Protein Expression from Neonates to Children. <i>Drug Metabolism and Disposition</i> , <b>2017</b> , 45, 23-26	4	18
59	Learning Health Systems as Facilitators of Precision Medicine. <i>Clinical Pharmacology and Therapeutics</i> , <b>2017</b> , 101, 359-367	6.1	16
58	Fatty acid amide hydrolase-morphine interaction influences ventilatory response to hypercapnia and postoperative opioid outcomes in children. <i>Pharmacogenomics</i> , <b>2017</b> , 18, 143-156	2.6	8
57	Mycophenolate mofetil-related leukopenia in children and young adults following kidney transplantation: Influence of genes and drugs. <i>Pediatric Transplantation</i> , <b>2017</b> , 21, e13033	1.8	12
56	Intermediate term thrombotic risk in contemporary total cavo-pulmonary connection for single ventricle circulations. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2017</b> , 44, 275-280	5.1	8
55	Opportunities for model-based precision dosing in the treatment of sickle cell anemia. <i>Blood Cells, Molecules, and Diseases</i> , <b>2017</b> , 67, 143-147	2.1	4
54	Drug Dosing in Obese Children: Challenges and Evidence-Based Strategies. <i>Pediatric Clinics of North America</i> , <b>2017</b> , 64, 1417-1438	3.6	11
53	Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 254-260	5.1	12
52	Pharmacokinetics of IGF-1 in PAPP-A2-Deficient Patients, Growth Response, and Effects on Glucose and Bone Density. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 102, 4568-4577	5.6	24
51	Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial. <i>PLoS Medicine</i> , <b>2017</b> , 14, e1002428	11.6	21
50	A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 2220-2225	4.7	14
49	Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies. <i>Pediatrics</i> , <b>2016</b> , 137, e20153257	7.4	399
48	Genotype-Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 482-6	4.7	28

47	Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 307-315	4.7	95
46	Safety and Dose Escalation Study of Intravenous Zinc Supplementation in Pediatric Critical Illness. <i>Journal of Parenteral and Enteral Nutrition</i> , <b>2016</b> , 40, 860-8	4.2	16
45	Precision Dosing of Alemtuzumab: Population Pharmacokinetic Modeling in Pediatric Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Non-Malignant Diseases. <i>Blood</i> , <b>2016</b> , 128, 2203-2203	2.2	3
44	Individualized Dosing of Hydroxyurea for Children with Sickle Cell Anemia Using a Population Pharmacokinetic-Based Model: The TREAT Study. <i>Blood</i> , <b>2016</b> , 128, 3652-3652	2.2	2
43	Propofol Pharmacokinetics and Estimation of Fetal Propofol Exposure during Mid-Gestational Fetal Surgery: A Maternal-Fetal Sheep Model. <i>PLoS ONE</i> , <b>2016</b> , 11, e0146563	3.7	13
42	Pharmacokinetics of meropenem in children receiving continuous renal replacement therapy: Validation of clinical trial simulations. <i>Journal of Clinical Pharmacology</i> , <b>2016</b> , 56, 291-7	2.9	16
41	Milrinone Dosing Issues in Critically Ill Children With Kidney Injury: A Review. <i>Journal of Cardiovascular Pharmacology</i> , <b>2016</b> , 67, 175-81	3.1	12
40	Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 81, 742-52	3.8	26
39	Obesity and overweight as CAE comorbidities and differential drug response modifiers. <i>Neurology</i> , <b>2016</b> , 86, 1613-21	6.5	8
38	Pharmacokinetics and pharmacogenomics of $\beta$ -lactam-induced neutropenia. <i>Pharmacogenomics</i> , <b>2016</b> , 17, 547-59	2.6	5
37	A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 1829-1835	4.7	8
36	Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. <i>Neuro-Oncology</i> , <b>2015</b> , 17, 596-603	1	91
35	A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 1558-65	12.9	16
34	Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome: A Pilot Study. <i>Journal of Pediatrics</i> , <b>2015</b> , 167, 1214-20.e3	3.6	34
33	Impact of Laboratory Practices on Interlaboratory Variability in Therapeutic Drug Monitoring of Immunosuppressive Drugs. <i>Therapeutic Drug Monitoring</i> , <b>2015</b> , 37, 718-24	3.2	35
32	Population pharmacokinetic-pharmacodynamic modeling and dosing simulation of propofol maintenance anesthesia in severely obese adolescents. <i>Paediatric Anaesthesia</i> , <b>2015</b> , 25, 911-923	1.8	22
31	The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically-based pharmacokinetic model. <i>British Journal of Clinical Pharmacology</i> , <b>2015</b> , 80, 1438-46	3.8	20
30	Age-dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1. <i>Therapeutic Drug Monitoring</i> , <b>2015</b> , 37, 395-9	3.2	9



29	Retrospective Evaluation of Milrinone Pharmacokinetics in Children With Kidney Injury. <i>Therapeutic Drug Monitoring</i> , <b>2015</b> , 37, 792-6	3.2	11
28	Validation of a pediatric population pharmacokinetic model for vancomycin. <i>Therapeutic Drug Monitoring</i> , <b>2015</b> , 37, 413-6	3.2	13
27	Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS. <i>Journal of Visualized Experiments</i> , <b>2015</b> , e52424	1.6	11
26	Pharmacokinetics-Based Individualized Dosing Strategy to Predict Maximum Tolerated Dose of Hydroxyurea in Children with Sickle Cell Anemia. <i>Blood</i> , <b>2015</b> , 126, 982-982	2.2	
25	Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. <i>Lancet Infectious Diseases</i> , <b>2014</b> , 14, 498-509	25.5	534
24	Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatrics. <i>International Journal of Antimicrobial Agents</i> , <b>2014</b> , 43, 223-30	14.3	49
23	Current management of neonatal abstinence syndrome secondary to intrauterine opioid exposure. <i>Journal of Pediatrics</i> , <b>2014</b> , 165, 440-6	3.6	35
22	ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children. <i>Pharmacogenomics</i> , <b>2014</b> , 15, 1297-309	2.6	58
21	Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study. <i>Pediatric Blood and Cancer</i> , <b>2014</b> , 61, 982-6	3	65
20	Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period. <i>British Journal of Clinical Pharmacology</i> , <b>2014</b> , 78, 1102-12	3.8	10
19	Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 518-25	4.7	169
18	OCT1 genetic variants influence the pharmacokinetics of morphine in children. <i>Pharmacogenomics</i> , <b>2013</b> , 14, 1141-51	2.6	73
17	Evaluation of propofol anesthesia in morbidly obese children and adolescents. <i>BMC Anesthesiology</i> , <b>2013</b> , 13, 8	2.4	28
16	Developmental changes in morphine clearance across the entire paediatric age range are best described by a bodyweight-dependent exponent model. <i>Clinical Drug Investigation</i> , <b>2013</b> , 33, 523-34	3.2	49
15	Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1. <i>Therapeutic Drug Monitoring</i> , <b>2013</b> , 35, 332-7	3.2	23
14	A Phase I Trial Of Zileuton In Sickle Cell Disease. <i>Blood</i> , <b>2013</b> , 122, 993-993	2.2	5
13	Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. <i>British Journal of Clinical Pharmacology</i> , <b>2012</b> , 73, 727-40	3.8	32
12	Propofol Clearance in Morbidly Obese Children and Adolescents : Influence of Age and Body Size. <i>Clinical Pharmacokinetics</i> , <b>2012</b> , 51, 543-551	6.2	50

11	Propofol clearance in morbidly obese children and adolescents: influence of age and body size. <i>Clinical Pharmacokinetics</i> , <b>2012</b> , 51, 543-51	6.2	13
10	Morphine clearance in children: does race or genetics matter?. <i>Journal of Opioid Management</i> , <b>2012</b> , 8, 217-26	0.8	52
9	The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. <i>Clinical Pharmacokinetics</i> , <b>2011</b> , 50, 1-24	6.2	41
8	Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. <i>Transplantation Reviews</i> , <b>2011</b> , 25, 47-57	3.3	89
7	Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients. <i>Journal of Clinical Pharmacology</i> , <b>2011</b> , 51, 309-20	2.9	50
6	Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. <i>Clinical Transplantation</i> , <b>2008</b> , 22, 281-91	3.8	130
5	Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2007</b> , 51, 3049-55	5.9	40
4	Therapeutisches Drug Monitoring in der Pädiatrie / Therapeutic drug management in pediatric patients. <i>Laboratoriums Medizin</i> , <b>2007</b> , 31, 24-37		
3	Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2007</b> , 51, 3449-51	5.9	51
2	Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2003</b> , 47, 541-7	5.9	48
1	The application of population pharmacokinetic modeling to individualized antibiotic therapy. <i>International Journal of Antimicrobial Agents</i> , <b>2002</b> , 19, 313-22	14.3	33